192 related articles for article (PubMed ID: 23390503)
1. Additive toxicity of β-amyloid by a novel bioactive peptide in vitro: possible implications for Alzheimer's disease.
Garcia-Ratés S; Lewis M; Worrall R; Greenfield S
PLoS One; 2013; 8(2):e54864. PubMed ID: 23390503
[TBL] [Abstract][Full Text] [Related]
2. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments.
Kaneko I; Morimoto K; Kubo T
Neuroscience; 2001; 104(4):1003-11. PubMed ID: 11457586
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35.
Hope J; Shearman MS; Baxter HC; Chong A; Kelly SM; Price NC
Neurodegeneration; 1996 Mar; 5(1):1-11. PubMed ID: 8731376
[TBL] [Abstract][Full Text] [Related]
4. Discovering and targeting the basic mechanism of neurodegeneration: the role of peptides from the C-terminus of acetylcholinesterase: non-hydrolytic effects of ache: the actions of peptides derived from the C-terminal and their relevance to neurodegeneration.
Greenfield S
Chem Biol Interact; 2013 May; 203(3):543-6. PubMed ID: 23562497
[TBL] [Abstract][Full Text] [Related]
5. (I) Pharmacological profiling of a novel modulator of the α7 nicotinic receptor: Blockade of a toxic acetylcholinesterase-derived peptide increased in Alzheimer brains.
Garcia-Ratés S; Morrill P; Tu H; Pottiez G; Badin AS; Tormo-Garcia C; Heffner C; Coen CW; Greenfield SA
Neuropharmacology; 2016 Jun; 105():487-499. PubMed ID: 26867503
[TBL] [Abstract][Full Text] [Related]
6. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide.
Cottingham MG; Hollinshead MS; Vaux DJ
Biochemistry; 2002 Nov; 41(46):13539-47. PubMed ID: 12427014
[TBL] [Abstract][Full Text] [Related]
7. Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival.
Russo C; Violani E; Salis S; Venezia V; Dolcini V; Damonte G; Benatti U; D'Arrigo C; Patrone E; Carlo P; Schettini G
J Neurochem; 2002 Sep; 82(6):1480-9. PubMed ID: 12354296
[TBL] [Abstract][Full Text] [Related]
8. PC12 and neuro 2a cells have different susceptibilities to acetylcholinesterase-amyloid complexes, amyloid25-35 fragment, glutamate, and hydrogen peroxide.
Calderón FH; Bonnefont A; Muñoz FJ; Fernández V; Videla LA; Inestrosa NC
J Neurosci Res; 1999 Jun; 56(6):620-31. PubMed ID: 10374817
[TBL] [Abstract][Full Text] [Related]
9. Non-toxic conformer of amyloid β may suppress amyloid β-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease.
Izuo N; Murakami K; Sato M; Iwasaki M; Izumi Y; Shimizu T; Akaike A; Irie K; Kume T
Biochem Biophys Res Commun; 2013 Aug; 438(1):1-5. PubMed ID: 23747423
[TBL] [Abstract][Full Text] [Related]
10. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
11. Retro-inversal of intracellular selected β-amyloid-interacting peptides: implications for a novel Alzheimer's disease treatment.
Acerra N; Kad NM; Griffith DA; Ott S; Crowther DC; Mason JM
Biochemistry; 2014 Apr; 53(13):2101-11. PubMed ID: 24601543
[TBL] [Abstract][Full Text] [Related]
12. Uleine Disrupts Key Enzymatic and Non-Enzymatic Biomarkers that Leads to Alzheimer's Disease.
Seidl C; de Moraes Santos CA; De Simone A; Bartolini M; Weffort-Santos AM; Andrisano V
Curr Alzheimer Res; 2017; 14(3):317-326. PubMed ID: 27784218
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of Artemisia asiatica alkaloids on acetylcholinesterase activity from rat PC12 cells.
Heo HJ; Yang HC; Cho HY; Hong B; Lim ST; Park HJ; Kim KH; Kim HK; Shin DH
Mol Cells; 2000 Jun; 10(3):253-62. PubMed ID: 10901162
[TBL] [Abstract][Full Text] [Related]
14. Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.
Blanchard BJ; Konopka G; Russell M; Ingram VM
Brain Res; 1997 Nov; 776(1-2):40-50. PubMed ID: 9439794
[TBL] [Abstract][Full Text] [Related]
15. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
Gozes I; Divinski I; Piltzer I
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S3. PubMed ID: 19091000
[TBL] [Abstract][Full Text] [Related]
16. Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.
Jean L; Thomas B; Tahiri-Alaoui A; Shaw M; Vaux DJ
PLoS One; 2007 Jul; 2(7):e652. PubMed ID: 17653279
[TBL] [Abstract][Full Text] [Related]
17. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils.
Alvarez A; Alarcón R; Opazo C; Campos EO; Muñoz FJ; Calderón FH; Dajas F; Gentry MK; Doctor BP; De Mello FG; Inestrosa NC
J Neurosci; 1998 May; 18(9):3213-23. PubMed ID: 9547230
[TBL] [Abstract][Full Text] [Related]
18. Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage.
Mark RJ; Fuson KS; May PC
J Neurochem; 1999 Mar; 72(3):1146-53. PubMed ID: 10037487
[TBL] [Abstract][Full Text] [Related]
19.
Jean L; Brimijoin S; Vaux DJ
J Biol Chem; 2019 Apr; 294(16):6253-6272. PubMed ID: 30787102
[TBL] [Abstract][Full Text] [Related]
20. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
